Kevin Kunzmann

Cleveland Clinic lung transplant experts rejoin Lungcast to discuss optimization of the lung allocation system to continue reducing waitlist times and patient mortality.

New data show COPD and IPF, among other interstitial lung diseases, are more significantly associated with poor 30-day outcomes from COVID-19 than asthma.

The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.

New data from NIH investigators show acute respiratory distress syndrome from COVID-19 infection may trigger heart inflammation in patients.

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.

Isotretinoin was actually linked to a taller adult height among those who took it to treat acne in childhood versus doxycycline, in a new study.

New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.

Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.

Gelfand discusses the convenience of phototherapy, and how its efficacy may complement biologic regimens in patients with psoriasis.

New data from the Mayo Clinic show high BMI does not correlate with severe hidradenitis suppurativa in affected children and adolescents.

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.

Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

Thierry Passeron, MD, PhD, discusses the potential benefit of upadacitinib as an oral systemic therapy in patients with nonsegmental vitiligo.

Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.

The pioneer in neuroimmune research and itch physiology discusses how treatment innovation has evolved dermatology—and what still needs to be changed in practice.

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

With a couple of first-time therapies available for molluscum, Silverberg is interested in learning more about the disease's causes and manifestations.

James Q. Del Rosso, DO, discusses the recent report of benzene risk in benzoyl peroxide, as well as the need for active antibiotic monitoring in dermatology.

With drug breakthroughs reaching epidermolysis bullosa, Paller considers what may come next for other rare skin diseases.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

Boiko discusses the annual weeklong summer camp for children and adolescents with skin diseases to make connections, experience camp with the support of volunteer specialists, and find comfort with their condition.